血浆蛋白质组学未能识别抗凝期间及抗凝后静脉血栓栓塞复发的生物标志物:VISTA研究结果
基于VISTA试验的病例-队列研究,比较96例静脉血栓栓塞复发患者与192例随机亚队列患者,在维生素K拮抗剂治疗最后一个月及停药后1个月采集血浆,用无偏质谱蛋白质组学分析。主成分分析未显示复发与否存在整体蛋白质组差异,抗凝期间及停药后均未发现与复发有统计学显著相关的血浆蛋白水平变化。
要点
- 血浆蛋白质组学可反映抗凝效应,但未发现可预测静脉血栓栓塞复发的生物标志物。
- 复发患者与无复发患者之间无整体蛋白质组差异,亦无单个血浆蛋白水平变化达统计学显著。
- 配对采样显示个体间对抗凝启动和停用的反应存在差异,但该差异与复发无统计学显著关联。
核心结论
- 血浆蛋白质组学捕获了抗凝效应,但未揭示可预测静脉血栓栓塞复发的生物标志物,强调需要替代方法。
研究设计与样本
- 采用VISTA试验数据和样本的病例-队列研究,VISTA试验随访首次静脉血栓栓塞患者并接受维生素K拮抗剂治疗6个月,复发随访2年。
- 复发患者96例与随机选取的亚队列192例进行比较。
- 在维生素K拮抗剂治疗最后一个月及停药后1个月采集血浆。
- 使用无偏质谱蛋白质组学分析血浆蛋白。
主要发现
- 主成分分析显示复发患者与无复发患者之间无整体蛋白质组差异。
- 治疗期间及治疗后均未发现与复发有统计学显著相关的血浆蛋白水平变化。
- 配对采样显示个体间对维生素K拮抗剂治疗启动和停用的反应存在差异,包括维生素K拮抗剂依赖性凝血蛋白(如凝血酶原[因子II]、凝血因子VII、凝血因子XI、凝血因子X、维生素K依赖性蛋白S、蛋白C和蛋白Z)。
- 与复发相关的蛋白水平变化无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is typically treated with anticoagulation for 3 to 6 months. Decisions about extending treatment require balancing recurrence and bleeding risk. Current prediction models based on clinical markers lack sufficient discriminative accuracy, emphasizing the need for reliable biomarkers. OBJECTIVES: To identify plasma biomarkers associated with VTE recurrence during and after anticoagulation. METHODS: We conducted a case-cohort study using data and samples from the VISTA trial, which followed patients with a first VTE who were treated with vitamin K antagonists (VKAs) for 6 months. Follow-up for recurrence was 2 years. Recurrence cases (N = 96) were compared with a randomly selected subcohort (n = 192). Plasma was collected in the final month of VKA therapy and 1 month after cessation. Unbiased mass spectrometry-based proteomics was used to analyze plasma proteins. RESULTS: Principal component analysis revealed no global proteomic differences between patients with and without recurrence. In addition, no statistically significant changes in plasma protein levels were associated with recurrence, neither during nor after treatment. While paired sampling demonstrated variability in interindividual responses upon initiation and cessation of VKA treatment, including VKA-dependent coagulation proteins (eg, prothrombin [factor {F}II], coagulation FVII, FXI, FX, vitamin K-dependent protein S, protein C, and protein Z), there were no statistically significant differences in protein-level alterations associated with recurrence. CONCLUSION: While plasma proteomics captured anticoagulation effects, it did not reveal biomarkers predictive of VTE recurrence, underscoring the need for alternative approaches.
引用
- Smit ER, Poolen GC, van Duijl TT, et al. Plasma proteomics does not identify biomarkers of venous thromboembolism recurrence during and after anticoagulation: results from the VISTA study. J Thromb Haemost. 2025. PMID: 41397562. doi:10.1016/j.jtha.2025.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。